全文获取类型
收费全文 | 5613篇 |
免费 | 338篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 176篇 |
妇产科学 | 117篇 |
基础医学 | 806篇 |
口腔科学 | 247篇 |
临床医学 | 433篇 |
内科学 | 1533篇 |
皮肤病学 | 128篇 |
神经病学 | 568篇 |
特种医学 | 131篇 |
外科学 | 455篇 |
综合类 | 8篇 |
一般理论 | 1篇 |
预防医学 | 296篇 |
眼科学 | 26篇 |
药学 | 362篇 |
中国医学 | 5篇 |
肿瘤学 | 684篇 |
出版年
2024年 | 12篇 |
2023年 | 52篇 |
2022年 | 139篇 |
2021年 | 179篇 |
2020年 | 114篇 |
2019年 | 135篇 |
2018年 | 162篇 |
2017年 | 110篇 |
2016年 | 143篇 |
2015年 | 167篇 |
2014年 | 243篇 |
2013年 | 299篇 |
2012年 | 468篇 |
2011年 | 432篇 |
2010年 | 255篇 |
2009年 | 222篇 |
2008年 | 402篇 |
2007年 | 393篇 |
2006年 | 374篇 |
2005年 | 368篇 |
2004年 | 306篇 |
2003年 | 294篇 |
2002年 | 306篇 |
2001年 | 31篇 |
2000年 | 15篇 |
1999年 | 24篇 |
1998年 | 50篇 |
1997年 | 45篇 |
1996年 | 31篇 |
1995年 | 37篇 |
1994年 | 28篇 |
1993年 | 13篇 |
1992年 | 18篇 |
1991年 | 16篇 |
1990年 | 15篇 |
1989年 | 9篇 |
1988年 | 10篇 |
1987年 | 3篇 |
1986年 | 16篇 |
1985年 | 6篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 5篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有6005条查询结果,搜索用时 15 毫秒
171.
Renée T. Fortner Anika Hüsing Laure Dossus Anne Tjønneland Kim Overvad Christina C. Dahm Patrick Arveux Agnès Fournier Marina Kvaskoff Matthias B. Schulze Manuela Bergmann Antonia Trichopoulou Anna Karakatsani Carlo La Vecchia Giovanna Masala Valeria Pala Amalia Mattiello Rosario Tumino Fulvio Ricceri Carla H. van Gils Evelyn M. Monninkhof Catalina Bonet José Ramón Quirós Maria-Jose Sanchez Daniel-Ángel Rodríguez-Palacios Aurelio B Gurrea Pilar Amiano Naomi E. Allen Ruth C. Travis Marc J. Gunter Vivian Viallon Elisabete Weiderpass Elio Riboli Rudolf Kaaks 《International journal of cancer. Journal international du cancer》2020,147(5):1325-1333
Endometrial cancer (EC) incidence rates vary ~10-fold worldwide, in part due to variation in EC risk factor profiles. Using an EC risk model previously developed in the European EPIC cohort, we evaluated the prevention potential of modified EC risk factor patterns and whether differences in EC incidence between a European population and low-risk countries can be explained by differences in these patterns. Predicted EC incidence rates were estimated over 10 years of follow-up for the cohort before and after modifying risk factor profiles. Risk factors considered were: body mass index (BMI, kg/m2), use of postmenopausal hormone therapy (HT) and oral contraceptives (OC) (potentially modifiable); and, parity, ages at first birth, menarche and menopause (environmentally conditioned, but not readily modifiable). Modeled alterations in BMI (to all ≤23 kg/m2) and HT use (to all non-HT users) profiles resulted in a 30% reduction in predicted EC incidence rates; individually, longer duration of OC use (to all ≥10 years) resulted in a 42.5% reduction. Modeled changes in not readily modifiable exposures (i.e., those not contributing to prevention potential) resulted in ≤24.6% reduction in predicted EC incidence. Women in the lowest decile of a risk score based on the evaluated exposures had risk similar to a low risk countries; however, this was driven by relatively long use of OCs (median = 23 years). Our findings support avoidance of overweight BMI and of HT use as prevention strategies for EC in a European population; OC use must be considered in the context of benefits and risks. 相似文献
172.
173.
174.
Giovanna Montesano Piergiulio Cappelletti Domenico Caputo Barbara Liguori Assunta Campanile Concetta Rispoli 《Materials》2022,15(7)
The present paper assesses petrographic, mineralogical, chemical, and technological features of different zeolitic tuff samples from various western USA districts of the Basin and Range Province containing mainly erionite, mordenite, clinoptilolite/heulandite and phillipsite. The aim of this characterization is to evaluate the pozzolanic activity of these samples according to European normative UNI-EN 196/5 (Fratini test) to program a possible use as addition for blended cements. Petrographic and mineralogical results show that the two phillipsite-bearing tuffs have a higher theoretical Cation Exchange Capacity (CEC) than the other samples; technological characterization shows a pozzolanic behavior for all the samples but higher for the tuff samples containing phillipsite, which shows a higher reactivity with CaO. All the samples could be thus advantageously employed for the preparation of blended cements, potentially reducing CO2 emissions by 70–90%. 相似文献
175.
Paolo Tessari Alessandro Toffolon Monica Vettore Elisabetta Iori Anna Lante Emiliano Feller Elisabetta Alma Rocco Monica Vedovato Giovanna Verlato Massimo Bellettato 《Nutrients》2022,14(8)
Human milk contains <50% less protein (casein) than cow milk, but is equally effective in insulin secretion despite lower postingestion hyperaminoacidemia. Such potency of human milk might be modulated either by incretins (glucagon-like polypeptide-1,GLP-1); glucose-inhibitory-polypeptide, GIP), and/or by milk casein content. Healthy volunteers of both sexes were fed iso-lactose loads of two low-protein milks, i.e., human [Hum] (n = 8) and casein-deprived cow milk (Cow [↓Cas]) (n = 10), as well as loads of two high-protein milks, i.e., cow (n = 7), and casein-added human-milk (Hum [↑Cas]) (n = 7). Plasma glucose, insulin, C-peptide, incretins and amino acid concentrations were measured for 240′. All milks induced the same transient hyperglycemia. The early [20′–30′] insulin and C-peptide responses were comparable among all milk types apart from the low-protein (Cow [↓Cas]) milk, where they were reduced by <50% (p < 0.05 vs. others). When comparing the two high-protein milks, GLP-1 and GIP [5’–20’] responses with the (Hum [↑Cas]) milk were lower (by ≈2–3 fold, p < 0.007 and p < 0.03 respectively) than those with cow milk, whereas incretin secretion was substantially similar. Plasma amino acid increments largely reflected the milk protein content. Thus, neither casein milk content, nor incretin or amino acid concentrations, can account for the specific potency of human milk on insulin secretion, which remains as yet unresolved. 相似文献
176.
The placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family that has been shown to play an important role in promoting adult pathological angiogenesis. Besides inducing its own signaling in endothelial cells, PlGF exerts its angiogenic action by synergising with VEGF. In the skin, PlGF expression is upregulated during wound healing and PlGF-deficient mice show delayed wound closure, indicating that this factor promotes angiogenesis during skin repair. Moreover, PlGF expression by melanoma cells has been linked to tumor growth. The analysis of a transgenic mouse model constitutively expressing high levels of PlGF in basal keratinocytes has shown that this factor has strong angiogenic properties in the skin during both embryonic and post-natal life. Furthermore, PlGF delivery to the skin via an adenoviral vector induces the formation of large and stable blood vessels, but contrary to VEGF application, does not affect lymphatic vessel functionality. Such evidence opens the possibility of employing PlGF for therapeutic modulation of skin angiogenesis. 相似文献
177.
Parodi E Nobili B Perrotta S Rosaria Matarese SM Russo G Licciardello M Zecca M Locatelli F Cesaro S Bisogno G Giordano P De Mattia D Ramenghia U 《International journal of hematology》2006,84(1):48-53
This retrospective study investigated the effects of rituximab in 19 pediatric patients (15 girls and 4 boys) with chronic refractory symptomatic immune thrombocytopenic purpura (ITP). Patients received from 2 to 5 weekly infusions of rituximab (375 mg/m(2)); 15 patients were younger than 12 years when treated. The median follow-up time was 30 months (range, 9-43 months). The overall response rate was 68% (13/19 patients). Six responders relapsed at a median of 4.5 months (range, 3-8 months). Seven patients still displayed a platelet count >150,000/microL at a median of 33 months (range, 14-43 months) after rituximab treatment. Six of 15 patients treated with 4 or 5 weekly infusions and 1 of 4 patients treated with 2 or 3 infusions are still in remission. No difference was detected between splenectomized and nonsplenectomized patients. The duration of ITP disease at the time of treatment did not influence the response rate. Patients still in remission showed significantly lower levels of CD19+ cells after 4 and 6 months than nonresponding or relapsed patients (P < .05). No major infections were reported during follow-up. Our data show the efficacy and tolerability of rituximab in young children with refractory symptomatic ITP. Nonrelapsed patients showed a more prolonged B-cell depletion. 相似文献
178.
Calabrò P Limongelli G Maddaloni V Vizza CD D'Alto M D'Alessandro R Poscia R Argiento P Ziello B Badagliacca R Romeo E Pacileo G Russo MG Fedele F Calabrò R 《Internal and emergency medicine》2012,7(5):425-430
This study analyses the frequency and the potential role of two polymorphisms, the +134del/insA, located in the gene encoding for Endothelin-1 (EDN1), and the His323His in the gene encoding for Endothelin receptor type A (EDNRA) in a cohort of 98 consecutive patients with pulmonary arterial hypertension from two different Cardiology Units (Mid-South of Italy), and in 100 healthy Caucasian subjects randomly recruited from the same area. Cardiac anatomy and function were analysed by non invasive diagnostic imaging techniques (Echocardiography standard m-mode, 2D, colour-Doppler) and by invasive studies (cardiac catheterization). Molecular screening of the region of interest was performed by automated sequencing. At univariate analysis, patients with the His323His TT genotype show a lower cardiac index (2 ± 0.6 vs. 2.3 ± 0.6; p = 0.05) and a higher indexed pulmonary vascular resistance (18.8 ± 9.6 vs. 14.2 ± 6.9; p = 0.01) at cardiac catheterization. A logistic multivariate model shows idiopathic disease (p = 0.01; OR = 3.8; CI = 1.3-11) and indexed pulmonary vascular resistances (p = 0.01; OR = 1.1; CI = 1-1.2) as independent predictors of TT genotype. Our findings may suggest a potential link between specific genotypes in the EDNRA gene and susceptibility for PAH. 相似文献
179.
180.
Mazza C Buzi F Ortolani F Vitali A Notarangelo LD Weber G Bacchetta R Soresina A Lougaris V Greggio NA Taddio A Pasic S de Vroede M Pac M Kilic SS Ozden S Rusconi R Martino S Capalbo D Salerno M Pignata C Radetti G Maggiore G Plebani A Notarangelo LD Badolato R 《Clinical immunology (Orlando, Fla.)》2011,139(1):6-11
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autosomal recessive organ-specific autoimmune disorder that is characterized by a variable combination of (i) chronic mucocutaneous candidiasis, (ii) polyendocrinopathy and/or hepatitis and (iii) dystrophy of the dental enamel and nails. We analyzed the AIRE (autoimmune regulator) gene in subjects who presented any symptom that has been associated with APECED, including candidiasis and autoimmune endocrinopathy. We observed that 83.3% of patients presented at least two of the three typical manifestations of APECED, while the remaining 16.7% of patients showed other signs of the disease. Analysis of the genetic diagnosis of these subjects revealed that a considerable delay occurs in the majority of patients between the appearance of symptoms and the diagnosis. Overall, the mean diagnostic delay in our patients was 10.2 years. These results suggest that molecular analysis of AIRE should be performed in patients with relapsing mucocutaneous candidiasis for early identification of APECED. 相似文献